These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27035234)

  • 41. Mutational and clinical spectrum of centronuclear myopathy in 9 cases and a literature review of Chinese patients.
    Wang Q; Yu M; Xie Z; Liu J; Wang Q; Lv H; Zhang W; Yuan Y; Wang Z
    Neurol Sci; 2022 Apr; 43(4):2803-2811. PubMed ID: 34595679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Centronuclear (myotubular) myopathy.
    Jungbluth H; Wallgren-Pettersson C; Laporte J
    Orphanet J Rare Dis; 2008 Sep; 3():26. PubMed ID: 18817572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease.
    Zhao M; Maani N; Dowling JJ
    Neurotherapeutics; 2018 Oct; 15(4):966-975. PubMed ID: 30426359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical and biopsy-based myopathological features of 5 cases with centronuclear myopathy].
    Li HH; Liu SP; Li W; Zhao YY; Wu JL; Li DN; Yan CZ
    Zhonghua Er Ke Za Zhi; 2008 Nov; 46(11):856-9. PubMed ID: 19099905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.
    Jungbluth H; Zhou H; Sewry CA; Robb S; Treves S; Bitoun M; Guicheney P; Buj-Bello A; Bönnemann C; Muntoni F
    Neuromuscul Disord; 2007 Apr; 17(4):338-45. PubMed ID: 17376685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.
    Trochet D; Prudhon B; Beuvin M; Peccate C; Lorain S; Julien L; Benkhelifa-Ziyyat S; Rabai A; Mamchaoui K; Ferry A; Laporte J; Guicheney P; Vassilopoulos S; Bitoun M
    EMBO Mol Med; 2018 Feb; 10(2):239-253. PubMed ID: 29246969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Centronuclear myopathy with cataracts due to a novel dynamin 2 (DNM2) mutation.
    Jungbluth H; Cullup T; Lillis S; Zhou H; Abbs S; Sewry C; Muntoni F
    Neuromuscul Disord; 2010 Jan; 20(1):49-52. PubMed ID: 19932620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A centronuclear myopathy-causing mutation in dynamin-2 disrupts neuronal morphology and excitatory synaptic transmission in a murine model of the disease.
    Arriagada-Diaz J; Flores-Muñoz C; Gómez-Soto B; Labraña-Allende M; Mattar-Araos M; Prado-Vega L; Hinostroza F; Gajardo I; Guerra-Fernández MJ; Bevilacqua JA; Cárdenas AM; Bitoun M; Ardiles AO; Gonzalez-Jamett AM
    Neuropathol Appl Neurobiol; 2023 Aug; 49(4):e12918. PubMed ID: 37317811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations in dynamin 2 cause dominant centronuclear myopathy.
    Bitoun M; Maugenre S; Jeannet PY; Lacène E; Ferrer X; Laforêt P; Martin JJ; Laporte J; Lochmüller H; Beggs AH; Fardeau M; Eymard B; Romero NB; Guicheney P
    Nat Genet; 2005 Nov; 37(11):1207-9. PubMed ID: 16227997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Centronuclear myopathies: a widening concept.
    Romero NB
    Neuromuscul Disord; 2010 Apr; 20(4):223-8. PubMed ID: 20181480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Paraspinal amyotrophy in DNM-2-related centronuclear myopathy.
    Kakiuchi K; Unoda K; Nakajima H; Nishino I; Arawaka S
    J Neurol Sci; 2019 Dec; 407():116537. PubMed ID: 31655408
    [No Abstract]   [Full Text] [Related]  

  • 52. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.
    Tasfaout H; Buono S; Guo S; Kretz C; Messaddeq N; Booten S; Greenlee S; Monia BP; Cowling BS; Laporte J
    Nat Commun; 2017 Jun; 8():15661. PubMed ID: 28589938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Respiratory features of centronuclear myopathy in the Netherlands.
    Bouma S; Cobben N; Bouman K; Gaytant M; van de Biggelaar R; van Doorn J; Reumers SFI; Voet NB; Doorduin J; Erasmus CE; Kamsteeg EJ; Jungbluth H; Wijkstra P; Voermans NC
    Neuromuscul Disord; 2023 Jul; 33(7):580-588. PubMed ID: 37364426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin.
    Massana Muñoz X; Kretz C; Silva-Rojas R; Ochala J; Menuet A; Romero NB; Cowling BS; Laporte J
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32809972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset.
    Bitoun M; Bevilacqua JA; Prudhon B; Maugenre S; Taratuto AL; Monges S; Lubieniecki F; Cances C; Uro-Coste E; Mayer M; Fardeau M; Romero NB; Guicheney P
    Ann Neurol; 2007 Dec; 62(6):666-70. PubMed ID: 17932957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Satellite cells deficiency and defective regeneration in dynamin 2-related centronuclear myopathy.
    F Almeida C; Bitoun M; Vainzof M
    FASEB J; 2021 Apr; 35(4):e21346. PubMed ID: 33715228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Necklace" fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy.
    Bevilacqua JA; Bitoun M; Biancalana V; Oldfors A; Stoltenburg G; Claeys KG; Lacène E; Brochier G; Manéré L; Laforêt P; Eymard B; Guicheney P; Fardeau M; Romero NB
    Acta Neuropathol; 2009 Mar; 117(3):283-91. PubMed ID: 19084976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical, genetic, and histological features of centronuclear myopathy in the Netherlands.
    Reumers SFI; Erasmus CE; Bouman K; Pennings M; Schouten M; Kusters B; Duijkers FAM; van der Kooi A; Jaeger B; Verschuuren-Bemelmans CC; Faber CG; van Engelen BG; Kamsteeg EJ; Jungbluth H; Voermans NC
    Clin Genet; 2021 Dec; 100(6):692-702. PubMed ID: 34463354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RYR1-Related Myopathies: Clinical, Histopathologic and Genetic Heterogeneity Among 17 Patients from a Portuguese Tertiary Centre.
    Samões R; Oliveira J; Taipa R; Coelho T; Cardoso M; Gonçalves A; Santos R; Melo Pires M; Santos M
    J Neuromuscul Dis; 2017; 4(1):67-76. PubMed ID: 28269792
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autosomal dominant congenital fibre type disproportion: a clinicopathological and imaging study of a large family.
    Sobrido MJ; Fernández JM; Fontoira E; Pérez-Sousa C; Cabello A; Castro M; Teijeira S; Alvarez S; Mederer S; Rivas E; Seijo-Martínez M; Navarro C
    Brain; 2005 Jul; 128(Pt 7):1716-27. PubMed ID: 15857933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.